BIOTECHNOLOGY EUROPE NEWS

Community

Advertising Opportunities

Biotechnology Europe Programs

Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe

BIOTECHNOLOGY EUROPE-DENMARK NEWS

24.02.2010 Lundbeck expands the agreement with Teva to include marketing of Azilect® in selected Asian countries

30.10.2009 Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline

28.10.2009 CLC bio to expand into Japanese market, accepts Filgen as its reseller

24.09.2009 Results of ADAGIO study with Azilect® in Parkinson's disease published in The New England Journal of Medicine

30.07.2009 Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued

07.07.2009 Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies

02.07.2009 Lu AA24530 shows positive results in major depressive disorder phase II study

25.06.2009 Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia

08.06.2009 Update on Lu AA21004 clinical development programme in major depressive disorder (MDD)

18.05.2009 Lundbeck provides update on NDA for Serdolect® for the treatment of schizophrenia

08.04.2009 FDA Advisory Committee provides opinion on Serdolect® for the treatment of schizophrenia

02.04.2009 Notice of the annual general meeting

I back I top I

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com